Literature DB >> 28905372

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

Swapna Thota1,2, Bhumika J Patel1,2, Meena Sadaps1, Suresh Balasubramanian1, Srinivasa Sanikommu1, Cassandra Hirsch1, Serena Marotta3, Mikkael A Sekeres2, Antonio M Risitano3, Jaroslaw P Maciejewski1.   

Abstract

Entities:  

Keywords:  T- LGL; alemtuzumab; aplastic anaemia; bone marrow failure; pure red cell aplasia

Mesh：

Substances：

Year:  2017        PMID： 28905372     DOI： 10.1111/bjh.14907

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  Aplastic Anemia.

Authors:  Neal S Young
Journal:  N Engl J Med       Date:  2018-10-25       Impact factor: 91.245

2.  Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis.

Authors:  Jarrett Madeley; Georgina Hodges; Andrew Birchley
Journal:  BMJ Case Rep       Date:  2018-10-17

3.  How I manage acquired pure red cell aplasia in adults.

Authors:  Carmelo Gurnari; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2021-04-15       Impact factor: 22.113

4.  Rational management approach to pure red cell aplasia.

Authors:  Suresh Kumar Balasubramanian; Meena Sadaps; Swapna Thota; Mai Aly; Bartlomiej P Przychodzen; Cassandra M Hirsch; Valeria Visconte; Tomas Radivoyevitch; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.